Clinical Research Study

 
News Articles for Clinical Research Study top ^
2014/12/15
Alkermes plc (NASDAQ: ALKS) today announced the initiation of a phase 1 clinical study of extended dosing intervals of aripiprazole lauroxil, the company’s investigational, novel, long-acting injectable atypical antipsychotic for the treatment of schizophrenia.
Sign-up for Alkermes Announces Initiation of Clinical Study of Extended Durations of Aripiprazole Lauroxil for Treatment of Schizophrenia investment picks
2015/2/5
The New England Journal of Medicine Publishes Positive Results from Clinical Study of Neovasc's Reducer Product Canada NewsWire NASDAQ: NVCN TSX: NVC VANCOUVER , Feb.
Sign-up for The New England Journal of Medicine Publishes Positive Results from Clinical Study of Neovasc's Reducer Product investment picks
2015/2/27
SUNNYVALE, Calif.
Sign-up for In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody investment picks
2015/2/16
http://www.marketwire.com/library/MwGo/2015/2/13/11G033197/Acura_Pharmaceuticals,_Inc.-6733629489.jpg PALATINE, IL--(Marketwired - February 16, 2015) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), today announced the initiation of treatment in a pilot clinical study of two experimental formulations of NEXAFED (pseudoephedrine HCl) extended-release tablets employing Acura's 2 nd generation methamphetamine resistant technology, IMPEDE 2.0. The study in fasted, healthy subjects will measure the systemic absorption of the active ingredient, pseudoephedrine, from two experimental NEXAFED extended-release formulations compared to an FDA-approved 12-hour extended-release reference product.
Sign-up for Acura Pharmaceuticals Initiates Clinical Study of Meth-Resistant Nexafed(R) Extended-Release Formulations investment picks
2015/1/12
http://www.marketwire.com/library/MwGo/2015/1/11/11G030102/Logo1-1973187467.jpg NEWARK, CA--(Marketwired - January 12, 2015) - CymaBay Therapeutics Inc. (NASDAQ: CBAY) today announced positive preliminary results from its clinical study of arhalofenate administered in combination with febuxostat (Uloric™, Takeda Pharmaceutical Company Limited). Arhalofenate is a once-daily, oral candidate for the treatment of gout with a unique dual mechanism of action which lowers serum uric acid (sUA) while also reducing the occurrence of gout flares.
Sign-up for Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat investment picks
2014/12/9
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that dosing has begun in a Phase IIa clinical study evaluating whether its investigational guanylate cyclase-C (GC-C) agonist, IW-9179, can provide symptomatic relief to patients with diabetic gastroparesis.
Sign-up for Ironwood Pharmaceuticals Initiates Phase IIa Clinical Study of IW-9179 in Diabetic Gastroparesis investment picks
2015/1/7
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the first patient enrollment in the STAR-VT ( S ubstrate T argeted A blation using the FlexAbility™ Ablation Catheter System for the R eduction of V entricular T achycardia) clinical trial, a prospective, multi-center, randomized study evaluating the safety and efficacy of the FlexAbility™ ablation catheter when used in ventricular tachycardia (VT) ablation procedures.
Sign-up for St. Jude Medical Begins Landmark Clinical Study to Evaluate Effectiveness of Ablation Procedures for Treatment of Ventricular Tachycardia investment picks
2014/12/31
VANCOUVER, British Columbia, Dec.
Sign-up for Tekmira Provides Update on TKM-PLK1 Phase I/II Clinical Study in Patients With Advanced Gastrointestinal Neuroendocrine Tumors and Adrenocortical Carcinoma investment picks
2015/2/24
http://www.marketwire.com/library/MwGo/2015/2/24/11G033927/Logo1-1296114052.jpg NEWARK, CA--(Marketwired - February 24, 2015) - CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced positive preliminary topline results from its Phase 2b clinical study of its lead product candidate, arhalofenate, for the treatment of gout.
Sign-up for CymaBay Therapeutics Announces Positive Results From Its Phase 2b Clinical Study Demonstrating That Arhalofenate Met the Primary Endpoint of Reduction in Gout Flares investment picks
2015/1/13
SAN DIEGO, California and TORONTO, Ontario , Jan.
Sign-up for Aptose Biosciences Doses First Patient in Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological Malignancies investment picks
2015/1/20
MIGDAL HA'EMEQ, Israel, Jan.
Sign-up for Enzymotec Ltd. Initiates Clinical Study of Vayacog in Mild Cognitive Impairment investment picks
2015/2/9
Aurinia Pharmaceuticals Inc. (the “Company”) (NASDAQ:AUPH) (TSX:AUP) today announced that it will initiate an open label, exploratory study to assess the short term predictors of response using voclosporin in combination with mycophenolate mofetil in patients with active lupus nephritis.
Sign-up for Aurinia Pharmaceuticals to Initiate an Open Label Clinical Study to Investigate the Impact of Voclosporin on Lupus Nephritis Biomarkers investment picks
2014/12/22
VANCOUVER, British Columbia, Dec.
Sign-up for Tekmira Establishes Manufacturing and Clinical Trial Agreement to Provide TKM-Ebola-Guinea for Clinical Studies in West Africa investment picks
2015/1/20
Trovagene's proprietary KRAS assay enables physicians to determine mutational status, monitor treatment response, and use genomics to aid in predicting patient prognosis SAN DIEGO , Jan.
Sign-up for Clinical Study Results Presented at the 2015 Gastrointestinal Cancer Symposium Support Utility of Trovagene's Precision Cancer Monitoring Platform in Colorectal and Pancreatic Cancer Patients investment picks
2014/12/18
SALT LAKE CITY, Dec.
Sign-up for Amedica Announces Preliminary Q4 & FY 2014 Financial Results and Update on CASCADE Clinical Study investment picks
2015/2/5
NASDAQ: NVCN TSX: NVC VANCOUVER , Feb.
Sign-up for The New England Journal of Medicine Publishes Positive Results from Clinical Study of Neovasc's Reducer Product investment picks
2015/2/11
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, today announced the initiation of a Phase 1 clinical trial of HTX-011, which is being developed for the treatment of post-operative pain.
Sign-up for Heron Therapeutics Initiates Phase 1 Clinical Study of HTX-011 for the Treatment of Post-Operative Pain investment picks
2014/12/22
VANCOUVER, British Columbia, Dec.
Sign-up for Tekmira Receives Clearance to Conduct a Phase I Clinical Study With TKM-HBV investment picks
2015/1/8
Pharming Group NV (EURONEXT: PHARM) and Salix Pharmaceuticals, Ltd.
Sign-up for Pharming and Salix Announce First Patient Treated in Clinical Study of Ruconest® for Prophylaxis of Hereditary Angioedema investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Clinical Research Study
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Clinical Research Programs  |  Next: Clinical Results